0
Summaries for Patients |

Colchicine Treatment for Recurrent Pericarditis FREE

[+] Article and Author Information

The full report is titled “Colchicine for Recurrent Pericarditis (CORP).” A Randomized Trial. It is in the 4 October 2011 issue of Annals of Internal Medicine (volume 155, pages 409-414). The authors are M. Imazio, A. Brucato, R. Cemin, S. Ferrua, R. Belli, S. Maestroni, R. Trinchero, D.H. Spodick, and Y. Adler, on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators.


Ann Intern Med. 2011;155(7):I-28. doi:10.7326/0003-4819-155-7-201110040-00360
Text Size: A A A

What is the problem and what is known about it so far?

Pericarditis is the inflammation of a sac that surrounds the heart. It can occur after cardiac surgery; from viral infections, tuberculosis, cancer, or an autoimmune disease; or, commonly, for no identifiable reason. Pericarditis usually causes pain and sometimes it causes life-threatening fluid accumulation around the heart. Although patients benefit from treatment with anti-inflammatory drugs (such as aspirin, ibuprofen, or a steroid), pericarditis frequently recurs. Recurrences are a troublesome complication of pericarditis, occurring in about one third of patients with acute pericarditis and up to 50% of patients with a first recurrence. Some patients have been treated with another drug, colchicine, although data from well-done clinical trials are limited.

Why did the researchers do this particular study?

To see whether colchicine can help resolve the symptoms and prevent further recurrences of pericarditis.

Who was studied?

120 patients who had a first recurrence of pericarditis.

How was the study done?

Patients were randomly assigned to receive either colchicine or a placebo pill every day for 6 months. Both groups also received anti-inflammatory drugs.

What did the researchers find?

Symptoms of pericarditis resolved within 1 week more often for patients who received colchicine than for those who received placebo. Patients who received colchicine had about half the number of additional episodes of pericarditis during the following 18 months than those who received placebo. Gastrointestinal symptoms (such as diarrhea, nausea, or discomfort) were the most frequent side effects, occurring in 7% of the patients in both groups.

What were the limitations of the study?

Patients whose pericarditis was caused by specific infections or cancer, women who were pregnant or breastfeeding, and those who had already had more than 1 recurrence of pericarditis were not studied. Whether colchicine would be beneficial or safe for such patients is unknown. It is also not known how long treatment should be continued. Colchicine is not approved for the treatment of pericarditis in the United States or Europe, and this use is considered off-label.

What are the implications of the study?

Colchicine is a safe and effective treatment for some patients who have had their first recurrence of pericarditis.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)